CORDIS · 101209208 · HORIZON
LINK-M Investigating the Interplay of Natural Killer Cells and Microbiome in Non-Hodgkin's Lymphoma
Coordinator: LUXEMBOURG INSTITUTE OF HEALTH (LU)
Natural Killer (NK) cells have a critical role in anti-cancer immunity and recently the influence of the microbiome in cancer immunotherapy was shown. Comprehending the complex interplay between the expression of NK cells ligands involved in immune evasion mechanisms and the microbiome is crucial for achieving immunotherapy success. Diffuse Large B Cell Lymphoma (DLBCL) and Follicular Lymphoma (FL) are two types of Non-Hodgkin Lymphomas (NHL) characterized by accumulating B lymphocytes in lymph nodes, and extranodal sites. DLBCL and FL usually show aggressive and indolent behavior respectivel…
About Horizon Europe (2021–2027)
Horizon Europe is the EU's current research and innovation programme, covering 2021 to 2027 with a budget of roughly €95.5 billion. Its three pillars are Excellent Science (frontier research and mobility), Global Challenges and European Industrial Competitiveness (mission-driven collaborative projects in health, climate, digital, security and food) and Innovative Europe (the EIC and EIT). It also funds five EU Missions targeting cancer, climate adaptation, smart cities, oceans and soils.
0 EU contribution: €216k awarded to the consortium. The project runs over approximately 2 years from 2026-09-01 to 2028-08-31.
Full record on CORDIS — partners, deliverables, publications, news.
Open on cordis.europa.eu → Grant DOI ↗More from LU
see all →- HEDGE-IoT — Holistic Approach towards Empowerment of the DiGitalization of the Energy Ecosystem through adoption of IoT solutions101136216 · HORIZON · €18.0M
- DESIDERATA — Integrated Pathways: Advancing Safe and Sustainable by Design Material Innovation through Collaborative Wisdom101178011 · HORIZON · €10.7M
- TrustChain — Fostering a Human-Centered, Trustworthy and Sustainable Internet101093274 · HORIZON · €10.6M
- HealthyW8 — Empowering healthy lifestyle behaviour through personalised intervention portfolios to prevent and control obesity during vulnerable stages of life101080645 · HORIZON · €10.0M
- PATH — Patient AI Treatment Hub101253520 · HORIZON · €8.9M
- ALCEMIST — Atypical Liquid Crystal Elastomers: from Materials Innovation to Scalable processing and Transformative applications101167171 · HORIZON · €8.5M
Other HORIZON projects
see all →- EUROfusion — Implementation of activities described in the Roadmap to Fusion during Horizon Europe through a joint programme of the members of the EUROfusion consortium101052200 · DE · €549.4M
- EITUM-BP26-28 — EIT Urban Mobility Business Plan 2026-2028101269525 · ES · €206.9M
- PARC — Partnership for the Assessment of Risks from Chemicals101057014 · FR · €200.0M
- EIT RM BP23-25 — EIT RawMatrials Business Plan 2023-2025101113034 · DE · €155.5M
- SGA1-HE — COST: Europe's most empowering research programme Strengthening science and innovation through research networking101052416 · BE · €153.0M
- EIT HEI — EIT Higher Education Initiative - Scaling Europe’s Innovation Ecosystems101270329 · DE · €130.0M
Frequently asked questions
- Who funds this research project?
- This project is funded by the European Union through the Horizon Europe (2021–2027) programme, under the HORIZON-TMA-MSCA-PF-EF funding scheme.
- What is the EU contribution?
- The European Commission contributes €216k.
- Which EU programme funds it?
- The project is funded under Horizon Europe (2021–2027), call HORIZON-MSCA-2024-PF-01.
- Who coordinates the project?
- The project is coordinated by LUXEMBOURG INSTITUTE OF HEALTH (LU).
- What is the project timeline?
- The project runs from 2026-09-01 to 2028-08-31 — approximately 2 years.
- Where can I find the full project record?
- The complete record — partners, deliverables, publications and news — is published on CORDIS under project ID 101209208.